Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

David Chang

Joshua Kazam

Arie Belldegrun

Allogene Therapeutics, Inc.

EV Therapeutics develops off-the-shelf neoantigen-based immunotherapies from tumor-derived extracellular vesicles (EVs) and formulates proprietary therapeutic vaccines to enhance cancer treatment efficacy. self-described.

EV Therapeutics

Therini Bio develops immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. It focuses on a clinical-stage pipeline aimed at treating severe neurological and retinal diseases.

Therini Bio

Li Lab of Computational Cancer Immunology focuses on cancer research, particularly on the computational analysis of immune responses in cancer. The lab has conducted various studies related to T cell receptor repertoires, mitochondrial transfer between cells, and cancer immunotherapy.

Li Lab of Computational Cancer Immunology

Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.

For additional information on our guidelines, please visit www.allogene.com/news-center#community-guidelines

Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Allogene Therapeutics positions are accessible via the Allogene Careers page at www.allogene.com/careers.

Perceptive Advisors

Jennison Associates

Surveyor Capital

T. Rowe Price

venBio Select Advisor

Cowen Investment Management

Deerfield Capital Management

Fidelity Management and Research Company

Franklin Templeton

Gilead Sciences

Allogene Therapeutics

Today, we honor the remarkable legacy of Dr. Martin Luther King Jr. His tireless dedication to equality, justice, and unity continues to inspire generations. $ALLO #MLK #DEIB

We look forward to presenting at the 42nd annual J.P. Morgan Healthcare Conference. Join us live or tune in to our webcast on Wednesday, January 10 at 8:15 am PT to learn more about our 2024 Vision and plans to redefine the future of CAR T. $ALLO #CART https://lnkd.in/eutcVm_C

We are pleased to announce a strategic partnership with Foresight Diagnostics Inc. The ability to pair our investigational "off-the-shelf" CAR T product with an accurate biomarker has provided the pathway to introduce CAR T in first-line LBCL. https://lnkd.in/guh_r569

Today Allogene announced a bold 2024 Platform Vision that aims to redefine the future of CAR T by leveraging the unique attributes of an allogeneic product. #CART $ALL0 https://lnkd.in/gC-qW-8P

Learn more about Allogene's 2024 Platform Vision and plans to redefine the future of CAR T. Join our upcoming conference call tomorrow at 2pm PT. https://lnkd.in/ga_kkBK5

Always grateful to get our team together for some much-deserved fun at the end of a busy year. Wishing you all safe and happy holiday!

Greater access to CAR T means both efficiacy and safety must be addressed. See our latest research at #ASH2023 booth #3205
https://lnkd.in/gDPBDdRD

The countdown to #ASH23 has begun! Visit our exhibit at booth #3205 and learn how AlloCAR T™ product candidates could fuel the next wave in cell therapy.

As CAR Ts change the treatment landscape, patient demand is straining the system. Could an "off-the-shelf” CAR T product usher in the next treatment wave? #CART #STATSummit2023

The #CART Story is far from being fully written! Our EVP of R&D and CMO, Zachary J Roberts MD PhD shares, "My hope for the future of cancer treatment is that we as a community continue to make breakthroughs that bring us closer to a cure."

Metric
Company Name	Allogene Therapeutics, Inc.	EV Therapeutics	Therini Bio	Li Lab of Computational Cancer Immunology
Symbol	ALLO
MSH ID	COM:ALLOGENE	COM:EVTHERAPEUTICS	COM:THERINIBIO	ORG:LILAB-UTSW
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US	US
Stage
Employee Count	232	1
Website	allogene.com	evtherapeutics.com	therinibio.com	lilab-utsw.org
LinkedIn	allogene-therapeutics		therinibio
Founders

Metric
Market Cap	498.99M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	95K
Revenue (LTM)
Revenue (NTM)
Gross Profit	95K
EBITDA	-287.05M
Operating Income	-314.49M
Net Income	-327.26M
EPS	-2.09
Diluted EPS	-2.09
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-68.24
Operating Profit Margin	-1.97K
EBITDA Margin	-3.02K
Net Profit Margin	-2.02K
Return on Equity	-0.53
Return on Assets	-0.43
Return on Capital Employed	-0.44

COM:ALLOGENE

Allogene Therapeutics, Inc.

Last Close

2.11

22/11 21:00

Market Cap

498.99M

Beta: -

Volume Today

1.42M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-2.13
P/B Ratio	1.21
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	7.08K
EV Multiple	-1.44

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle	8.49K
Cash Conversion Cycle	8.42K
Asset Turnover	0.00

Metric
Operating Cash Flow	-237.73M
Free Cash Flow	-239.25M
Cash Flow to Debt	-2.37
Operating Cash Flow/Sales	-1.49K
Free Cash Flow Yield	-0.35

Metric
Cash & Equivalents	83.16M
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization	0.17
Debt to Assets	0.13
Current Ratio	12.58
Quick Ratio	12.80

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	365.40
R&D to Revenue	1.42K
SG&A to Revenue	405.65